Chad M. Jennings

Mr. Jennings’ recent experience includes representing:

Biopharmaceuticals and Biologics

• The underwriters on Alpine Immune Sciences’ US$100 million IPO
• Arcutis Biotherapeutics, an early commercial-stage biopharmaceutical company focused on immuno-dermatology, on its public offering
• The underwriters on Chinook Therapeutics’ US$105 million public offering
• The initial purchasers in Cytokinetics’ US$540 million convertible senior notes offering
• Geron, a late-stage clinical biopharmaceutical company, on its US$198 million upsized initial public offering (IPO)
• The initial purchasers in Halozyme Therapeutics’ upsized private offering of US$625 million of convertible senior notes
• Hercules Capital on:
  • A financing agreement for Kura Oncology, a clinical-stage biopharmaceutical company
  • Tricida’s US$125 million debt facility
• HilleVax on its upsized IPO
• The lenders to support Kindeva Drug Delivery’s combination with Meridian Medical Technologies to create a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products
• Ligand Pharmaceuticals on completing the spln-off off its OmniAb antibody discovery business and its subsequent business combination with Avista Public Acquisition Corp. II, resulting in OmniAb becoming an independent publicly traded company
• Mineralys Therapeutics, a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, on its upsized IPO
• The underwriters in Mirum Pharmaceuticals’ public offering
• Rhythm Pharmaceuticals in a revenue interest financing agreement with HealthCare Royalty Partners for up to US$100 million
• The underwriters in a US$600 million public offering for Vaxcyte, a clinical-stage vaccine innovation company engineering high-fidelity vaccines

Medical Device and Medical Technology

• AcuFocus, a privately held ophthalmic medical device company, on its acquisition by a Bausch + Lomb affiliate
• Affera in its sale to Medtronic
• Alphatec Holdings, a medical technology company focused on surgical treatment for spinal disorders, on a US$150 million nondilutive term loan agreement with life sciences firm Braidwell
• The direct lender to support AWA Investors’ acquisition of Burke Porter Group, a global provider of automated diagnostic, testing, and production solutions, from CEL Global Investment Fund
• ICU Medical in its US$1 billion acquisition of Pfizer’s Hospira Infusion Systems business
• MedAlliance on its US$1.135 billion acquisition by Cordis
• SLR Capital Partners on US$300 million debt facilities for Outset Medical, a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis

Food

• Astorg and portfolio company Solina, a leading Euripean producer of savory ingredient solutions for the food industry, on acquiring Saratoga Food Specialties in a carve-out transaction from Smithfield Foods